Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06972992 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC47 in Combination With Semaglutide
A Phase 1 study of Chronic Weight Management, sponsored by Ascletis Pharma (China) Co., Limited.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
- 1
- Study location
NCT06972992 is a Phase 1 study of Chronic Weight Management that has completed, run by Ascletis Pharma (China) Co., Limited. The registered enrollment target is 28 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06972992, a Phase 1 study of Chronic Weight Management, has completed, sponsored by Ascletis Pharma (China) Co., Limited.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
- 1
- Study location
Study Summary
This will be a phase I, randomized, double-blind, placebo-controlled. This study will be conducted in three periods: the screening period, the treatment period, and the follow-up period.
Conditions Studied
Interventions
- DRUG ASC47 +Semaglutide
- DRUG Placebo+Semaglutide
Study Locations (1)
Texas
- Ascletis Clinical Site - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2025-04-18 |
| Est. Completion | 2025-09-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06972992
The ClinicalTrials.gov registry entry for NCT06972992 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ascletis Pharma (China) Co., Limited, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Weight Management appearing as the primary indexed condition, and to 2 interventions - of which ASC47 +Semaglutide is the first listed.
NCT06972992 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT06972992 about?
NCT06972992 is a clinical study titled "A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC47 in Combination With Semaglutide". This will be a phase I, randomized, double-blind, placebo-controlled. This study will be conducted in three periods: the screening period, the treatment period, and the follow-up period.
What is the current status of trial NCT06972992?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2025-04-18. Estimated completion is 2025-09-22.
What conditions does trial NCT06972992 study?
This clinical trial studies the following conditions: Chronic Weight Management.
What interventions are being tested in trial NCT06972992?
The interventions under investigation include: ASC47 +Semaglutide (DRUG), Placebo+Semaglutide (DRUG).
Who is sponsoring clinical trial NCT06972992?
This trial is sponsored by Ascletis Pharma (China) Co., Limited, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06972992 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Weight Management
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ASC30 Injection in Participants With Obesity
ACTIVE NOT RECRUITING · Phase 1
-
A Dose-Range Study of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.